HealthEquity stock
HQYNASDAQHealthEquity, Inc., HealthcareISIN US42226A1079
71Score 71 out of 100, Strong
Price and trend
79 / 100
Price history
+2.5% in one yearThe chart shows daily closes over 12 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 15% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 48).
The price is 5.3% below its 52-week high. Largest decline in 12 years: 61% (November 2018 to December 2021).
Chart figures for advanced users
- SMA 50$95.99
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$89.86
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)48
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$73.21
- The lowest closing price of the last twelve months.
- Resistance$108.84
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- HealthEquity, Inc. belongs to the Medical (Healthcare Information Services) industry (United States) and, with a market value of $8.52B, is number 4 of 24 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $1.31B (up 9.5% year on year) and earnings of $215.2M (up 122.5%).
- For fiscal 2027, analysts expect on average revenue of $1.42B (up 7.9%) and adjusted earnings per share of $4.72 (up 17.8%).
Show more
- MEQIRI Score 71 out of 100 (Strong): rank 115 of 702 in Healthcare, median 53.
- The P/E is 36.6 (Medical (Healthcare Information Services) median 44.7, own median of recent years 99.5).
- Our model puts fair value at $118.68, with the price 13% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings per share growingUp 83.5% a year since 2021.Growth 91
- Earnings turn into cashFree cash flow 199% of earnings over the last 12 months.Fundamentals 79
- High marginNet margin 17.4% over the last 12 months, Medical (Healthcare Information Services) median 0.5%.Profitability 66
Weaknesses
- Margin may fall backOperating margin 24.6%, average of the prior years 10.9%, which ranged from 4.4% to 19.2%. After peaks like this, the margin was more than a quarter lower two years later in 44 of 100 cases, against 24 of 100 for other companies with high margins.Profitability 66
- DilutionShare count up 16% since 2021.Capital allocation 35
Its standout strengths are growth and fundamentals, while valuation and capital allocation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high growth grade (crashed more often in the backtest)
What lowers it
- solid fundamentals
- price near its 52-week high
Valuation
Valuation signal
Modestly undervaluedIn our model the price counts as cheap below $91.29 and expensive above $169.54 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $111.67 (cash-flow model) and $125.69 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 8.9%. At 9.9% the fair value would be $109.41, at 7.9% it would be $132.54.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (44.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 31 Jul 2026, revenue rose 7.3% on the twelve months before. Revenue has grown strongly since 2013, at around 29% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 70%, operating 25%, net 16%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 1 Dec 2026in 18 days
- Last reported
- 27 Aug 2026EPS reported $1.24 (expected $1.19)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $4.720.0%
- Revenue
- $1.42B0.0%
- Earnings per share
- $5.52+0.3%
- Revenue
- $1.52B−0.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −7.7%Fiscal 2027 guidance raised, revenue now $1.411 billion to $1.421 billion, average yield on HSA cash expected at 3.85% to 3.9%.
“We now expect average yield on HSA cash to be between 3.85% and 3.9% during fiscal 2027.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 27 Aug 2026 (fiscal Q2 2027), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $11,942 in total. 5 insiders sold, $2.46M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Rajasekar SunilPurchase
15 Oct 2026, EVP Chief Prod & Strat Officer
- Shares
- 108
- Price
- $90.33
- Value
- $9,756
- Dillon Adrian TSale
25 Aug 2026, Board
- Shares
- 7,632
- Price
- $104.61
- Value
- $798,373
- Rajasekar SunilSale
24 Aug 2026, EVP Chief Prod & Strat Officer
- Shares
- 108
- Price
- $105.60
- Value
- $11,405
Show 6 more
- Fiore Michael HenrySale
10 Jul 2026, EVP, CHIEF COMMERCIAL OFFICER
- Shares
- 2,354
- Price
- $95.00
- Value
- $223,630
- Rajasekar SunilPurchase
8 Jul 2026, EVP Chief Prod & Strat Officer
- Shares
- 23
- Price
- $95.06
- Value
- $2,186
- Fiore Michael HenrySale
2 Jul 2026, EVP, CHIEF COMMERCIAL OFFICER
- Shares
- 2,470
- Price
- $95.00
- Value
- $234,650
- Fiore Michael HenrySale
29 May 2026, EVP, CHIEF COMMERCIAL OFFICER
- Shares
- 3,142
- Price
- $95.00
- Value
- $298,490
- Wellborn Gayle FurgursonSale
28 May 2026, Board
- Shares
- 2,439
- Price
- $90.00
- Value
- $219,510
- Ladd DelanoSale
28 May 2026, EVP, General Counsel
- Shares
- 7,500
- Price
- $90.00
- Value
- $675,000
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at HealthEquity
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 71
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Healthcare Information Services)
The next larger and next smaller companies by market value
- BrightSpring Health ServicesBTSG $14.22B66
- Tempus AITEM $13.46B45
- Hinge HealthHNGE $9.83B70
- M32413.T $7.69B73
- Alibaba Health Information Technology0241.HK $6.02B59
- DoximityDOCS $5.92B82
- Waystar HoldingWAY $5.41B60
- HeartflowHTFL $5.21B47
ETFs that hold HealthEquity
Held by 14 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Harbor Health Care UCITS ETF AccW311 | 2.02% | 0.89% | €11.72M |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.46% | 0.30% | €185.82M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.29% | 0.30% | €4.28B |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.29% | 0.30% | €2.22B |
| State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4 | 0.26% | 0.30% | €5.36B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.15% | 0.43% | €2.5B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.08% | 0.35% | €8.27B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.07% | 0.10% | €395.74M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Jan 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 22 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.